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Clinical organ transplantation 
had its beginnings in 1902 with 
the report of an experimental or-
gan heterotransplant (kidney) by 
Ullmann. 1 Liver transplantation 
was conceived later. apparently 
by Welch2 in the early 19508. as a 
heterotopIc procedure. leaving the 
diseased organ in situ. Orthotopic 
liver transplantation in animals 
was first reported in 1956 by 
Cannon. but without the details. 
title. or identification of the ani-
mal used. 3 
f 
® 
Two research programs in liver 
transplantation were indepen-
dently established in 1958 in B0s-
ton and Chicago. Clinical applica-
tion was first performed in Den-
ver in March 1963; azathioprine 
(Imuran) and steroids were used 
for immunosuppression.4 ~----~~~~~---------~~------------~~ Because of poor initial results. 
a moratorium was voluntarily 
placed on human liver transplan-
tation for four years while further 
laboratory work continued. Mter 
the four years. clinical trials were 
resumed in Denver and in Cam-
bridge. England (by CaIne). with a 
one-year survival rate of about 
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33% in both locations.5 
In the beginning. liver trans-
plantation was performed with-
out the use of intraoperative ve-
nous bypasses. Blood loss was ex-
cessive. renal failure was com-
mon. and vascular anastomoses 
had to be done so quickly that 
teaching the procedure was al-
most impossible. As the central 
components of the procedure 
were refined. survival improved to 
modest levels. 
As time passed. more people 
continued 
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An international organ trans-
plant forum, to be held in Pitts-
burgh in September 1987, will 
honor Dr Starzl for his 25-year 
contribution to the field of or-
gan transplantation. 
were referred for liver transplan-
tation, but the availability of the 
operation was highly restricted. 
Liver transplantation was not an 
approved treatment for end-stage 
liver disease and was not covered 
by health insurance carriers, 
making the cost prohibitive. 
One of the greatest break-
throughs in liver transplantation 
occurred In 1978 with the Intro-
duction of cyclosporine (Sandim-
mune). First tested in England by 
Calne6 and shortly thereafter In 
the United States, cyclosporine 
represents one of the largest ad-
vances in transplantation surgery 
to date. SlITVl.val rates after liver 
transplantation improved to their 
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current overall level of 69% and 
55% at one and five years, respec-
tively. This improvement In sur-
vival has greatly Increased the ac-
ceptance of this procedure as a 
treatment method. 
In the mld-1980s, use of the 
venous bypass, first with hepa-
rinization and later without, re-
markably improved the practi-
cality of liver transplantation. 5.7 
Blood loss declined dramatically 
as did the Incidence of renal fail-
ure. More Important, perhaps, 
was that with the use of the by-
pass system, the procedure could 
be taught, and the surgical tech-
nique could be disseminated to 
other medical centers. 
As results with liver transplan-
tation Improved, more patients 
began to be referred In a premori-
bund state, which Increased their 
chances of surviving the opera-
tion. As stated earlier, use of the 
heparin-free bypass system dras-
tically reduced the requirement 
for blood products as well as the 
total operating time. 
As public awareness of the 
applicability of the procedure 
grew, pressure for acceptance of 
orthotopic liver transplantation 
as a viable treatment for end-
stage liver failure grew appropri-
ately. In 1983 at the National In-
stitutes of Health Consensus De-
velopment Conference on Liver 
Transplantatlon,8 the fruition of 
these labors was realized with the 
pronouncement that liver trans-
plantation was no longer consid-
ered an experimental procedure 
but a service operation for pa-
tients with Irreversible liver fail-
ure. After this announcement, 
many Insurance companies be-
gan reimbursement for hepatic 
replacement, thus extending to 
many this second chance for life. 
As Is Inevitable when a proce-
dure becomes economically prof-
Itable, its use greatly Increased. 
This was fortunate In that the 
number of centers doing the 
transplants was not adequate to 
meet the demand. However, 
many medical centers started liv-
er transplantation programs with 
few or no formally trained physl-
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'Additional centers in Georgia, California, New York, Utah, Michigan, Illinois, North 
Carolina, Virginia, Maryland, and Florida. 
cians or surgeons. Although pa-
tients must bear the "learning 
CUIVe" in the infancy of any pro-
cedure, this was not the case with 
liver transplantation, since the 
techniques had been refined and 
instruction was available to those 
who desired it. 
Liver transplantation today 
There are currently many new 
liver transplantation centers 
across the United States. with 
plans for a number of others to 
open. The number of transplants 
performed increases yearly, but 
demand still far outweighs the 
number of organs available. Even 
though the refinement of the flex-
ible procurement method9 allows 
nearly all of the transplantable or-
gans to be procured from a com-
mon donor. it still has not pro-
duced the number of organs need-
16 
ed annually. 
The busiest centers in the Unit-
ed States today. with the number 
of transplants performed in 1986 
(including retransplantation). are 
shown in table 1. 
Candidates and results 
Candidates for orthotopIc liver 
transplantation can be divided 
into several broad categories. Re-
sults of their operation usually de-
pend on the diagnosis. While this 
list by no means constitutes all in-
dications for transplantation, it 
does represent the most common 
current ones. 
VIRALCIRRHoslS--Chronic ac-
tive hepatitis is currently the most 
common indication for orthotopic 
liver transplantation in adults. 
Because these patients usually 
have severe portal hypertensIon 
and a small shrunken liver, 
continued 
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transplantation is often techni-
cally quite difficult. One-year sur-
vival rate is 67.2% but drops to 
50.9% at three years. These pa-
tients commonly have coexisting 
risk factors due to general poor 
health, making their long-term 
survival somewhat lower than av-
erage. If the causative virus was 
hepatitis B, recurrence has been 
the rule, and a number of such re-
cipients have come to retrans-
plantation. 
ALCOHOLIC CIRRBOSIS--Alco-
holic cirrhosis is considered sepa-
rately from nonalcoholic cirrhosis 
because the number of cases re-
quiring transplantation is small. 
The recipients often are in even 
poorer medical condition than pa-
tients with viral cirrhosis. Tech-
nically the operation is no harder 
to perform than that in other cir-
rhotic patients, but candidates 
must be selected with the greatest 
of care because recidivism is so 
prevalent among self-abuse 
groups. It is deSirable for the pa-
tient to demonstrate abstinence 
from alcohol before being consid-
ered for transplantation. 
PRIM.ARY BILIARY CIRRHOSIS--
A disease commonly affecting 
middle-aged women, primary bil-
iary cirrhOSis is the second most 
frequent indication for liver trans-
plantation in adults. The techni-
cal aspects of the operation are 
relatively easy, and the one- and 
five-year actuarial survival rates 
are both 68.4%. The disease is be-
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lieved to have an autoimmune 
etiology, with 85% to 90% of pa-
tients demonstrating antimito-
chondrial antibodies. 10 Immuno-
suppressant drugs, such as ste-
roids, azathioprine, chlorambucil 
(Leukoran). and cyclosporine, 
have all been tried without much 
success. II 10 date no cases have 
recurred after transplantation in 
our center. even though antlmtto-
chondrial antibody tests remain 
positive after transplantation in 
about 90% of cases. 12 Neuberger 
and associates l3 of Cambridge, 
England, have reported recur-
rences in the era before the avail-
ability of cyclosporine. 
SCLEROSING CHOLANGITIS-
Sclerosing cholangitis is a disease 
primarily of young men and is of-
ten associated with other disease 
entities, particularly inflammato-
ry bowel disease. Like primary bil-
iary cirrhosis it is considered most 
likely an autoimmune disorder, 
also without significant response 
to immunosuppressants. Unfor-
tunately, many of these patients 
have had previous operations in 
the hepatic hilum, and often they 
are not referred until all attempts 
at medical and surgical interven-
tion have been exhausted. These 
patients commonly present after 
multiple bouts of cholangitis, and 
many have cholangiocarcinomas 
coexisting with cirrhosis, making 
it too late for transplantation to ef-
fect a cure. The operation is mod-
erately difficult, but survival is 
currently 75.5% at one year and 
57% at three years. Posttrans-
plantation recurrence of scle-
rosing cholangitis has not been 
reported. 14 
TUMORS--The first orthotopic 
liver transplantations were done 
in patients with unresectable tu-
mor. It was thought that these pa-
tients would do well with trans-
plantation, since portal hyperten-
sion and its complications were 
usually absent. While short-term 
survival has been excellent, long-
term survival has been poor. 15 
Hepatoma is currently the most 
common primary liver tumor con-
sidered for transplantation. Pa-
tients found to have incidentalliv-
er malignancy at the time of 
transplantation for other causes 
have not had recurrence, but the 
same is not true when malignan-
cy was the reason for liver re-
placement. The recurrence rate 
has been at least 50% at one year; 
few of these patients are long-
term survivors. The exception to 
this is the subgroup of patients 
with fibrolamellar hepatoma, 
who have a one-year recurrence 
rate of 14.3% (1 in 7). The even-
tual recurrence rate in this 
subgroup is still quite high, but 
transplantation offers excellent 
palliation, even to those who are 
not ultimately cured. 
DUCT CELL CARCINOMA-Ac-
ceptance of these tumor patients 
for transplantation is not rou-
tine because long-term survival 
19 
has been essentially zero. If the 
diagnosis is known preoperative-
ly. patients should undergo radia-
tion therapy. If the tumor is dis-
covered incidentally in the hepa-
tectomy specimen. postoperative 
irradiation is recommended. 
Transplantation is still attempted 
for an occasional patient with the 
preoperative diagnosis of highly 
localized duct cell carcinoma. but 
thecarctnoma must be Wgh in the 
ductal system with no evidence of 
extrahepatic spread. 
INBORN ERRORS OF METABO-
LISM-This group encompasses 
both children and adults and in-
cludes such diseases as alpha I -
antitrypsin deficiency. hepatocel-
lular degeneration (Wilson's dis-
ease). cystic fibrosis. hemochro-
matosis. tyrosinemia. glycogen 
storage disease. hemophilia. and 
hypercholesterolemia. The opera-
tion is relatively easy. and results 
have been good. particularly in 
children. in whom the one- and 
five-year survival rate is 73.8%. 
BILIARY ATRESIA-BiliaIy atre-
sia is by far the most common in-
dication for orthotopic liver trans-
plantation in children. Most of 
these children have had right up-
per quadrant surgery, usually a 
portoenterostomy (Kasai proce-
dure) but occasionally a portosys-
temic shunt. While this has great-
ly increased morbidity. it has not 
negatively influenced Survival to a 
statistically significant extent. 16 
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Portoenterostomy may still be ap-
propriate for tiny children for 
whom donors are difficult to find. 
but repeated revisions and stomal 
creation are no longer justified. 
The difficulty of the operation de-
pends directly on previous right 
upper quadrant procedures. Ac-
tuarial survival is 68.4% at one 
year and 66.7% at five years. Be-
cause only small doses of predni-
sone are necessary. the children 
with biliary atresia who undergo 
transplantation have essentially 
normal growth and develop-
ment.17 
What'. new in Uver 
transplan1ation? 
Major new advances in technique 
will be rare. since the surgical 
technique in liver transplantation 
has been highly refmed. The field 
of immunosuppression. however, 
is relatively new and therefore 
open for major and almost contin-
uous breakthroughs. Several 
areas of immune modulation are 
currently under investigation or 
have recently finished clinical 
trials and should be considered by 
their separate mode of action or 
end result. 
Disease recurrence 
Alpha interferon. an immune 
substance manufactured by leu-
kocytes. is currently being inves-
tigated as an inhibiting agent for 
hepatitis B. In the first phase of 
study the drug is being given pre-
operatively to patients in an at-
tempt to rid the body of virus. It is 
also being perfused into the donor 
liver at the time of harvesting with 
the hope of making the liver more 
resistant to recurrence. If results 
prove to be encouraging. clinical 
trials will probably be extended to 
patients whose disease has re-
curred postoperatively. 
Prevention of acute rejection 
Monoclonal anti-T -lymphocyte 
antibody. or muromonab-CD3 
(Orthoclone OKT3). has just re-
cently been released for wide-
spread clinical use for the treat-
ment of steroid-resistant rejection 
in cyclosporine-treated patients. 
Results have been excellent (70% 
to 80% success rate). with few 
major side effects. IS 
Currently under investigation 
for the prevention of hyperacute 
rejection is platelet-activating fac-
tor receptor antagonist. both 
alone and in combination with 
prostaglandins. We have been 
able to show that in xenograft re-
nal transplantation (pig to dog). 
these drugs in combination dem-
onstrate significant abrogation of 
a very rapid and violent form of 
hyperacute r~ectionK It is hoped 
that the use of these drugs will 
prove extremely useful in pre-
venting the much less severe 
forms of rejection seen in the clin-
ical setting. 19 
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Long-term 
immunosuppression 
The final area of current investi-
gation is with new long-tenn im-
munosuppressive drugs. FR 
900506 (MW822) was isolated 
from Streptomyces tsukukacu-
sis, and 15-deoxysperguaIin (MW 
467) was isolated from sperguaIin 
taken from BaciUus latersporus. 
Both drugs have been shown to 
prolong cardiac and skin allograft 
survival in rodents. 
In in vitro studies, FR 900506 
has been found to exert its im-
munosuppressive effect by inhib-
iting T lymphocyte proliferation 
through inhibition of interleukin-
2 release. Interestingly, however, 
this inhibition is far stronger 
(on the order of 103) than cydo-
sporine. 
15-Deoxyspergualin has no ef-
fect on lymphocytes but has been 
found to act as a suppressor of the 
monocyte system, a novel mode of 
drug action in transplantation im-
munology. 
Summary and conclusions 
In summary. liver transplanta-
tion has truly come of age. To 
put things in perspective. the 
recipient waiting list at the Uni-
versity of Pittsburgh never in-
cludes fewer than 200 suitable 
candidates. and it continues to 
grow in spite of the fact that we 
are now doing essentially one 
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transplant per day. There are 
many excellent transplant cen-
ters throughout the United 
States and Europe. the only 
Umiting faetorbeing the supply 
of donors. 
Orthotopic liver transplanta-
tion is now covered by most 
major health insurance car-
riers. and some form of govern-
ment coverage is anticiplt.ted 
for the indigent. As the supply 
of donors increases with ag-
gressive education programs. 
the need for transplantation 
centers will also increase. How-
ever. this should not be uncon-
trolled growth. Mandatory 
training in transplantation sur-
gery will surely be requfrecI as a 
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